Pharmacogenetics and ethical considerations: Why care?

Pharmacogenomics Journal

Volumn 7, Issue 5, 2007, Pages 293-296

  Marx Stolting L ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOETHICS; CLINICAL COMPETENCE; CLINICAL PRACTICE; DOCTOR PATIENT RELATION; GENETIC SCREENING; INFORMATION STORAGE; INFORMED CONSENT; MEDICAL RESEARCH; PATIENT RIGHT; PHARMACOGENETICS; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; SOCIAL DISCRIMINATION; STIGMA;

BIOETHICAL ISSUES; CLINICAL COMPETENCE; ETHICS, CLINICAL; GENETIC PRIVACY; GENETIC SCREENING; GOVERNMENT REGULATION; GUIDELINES; HUMANS; INFORMED CONSENT; MENTAL COMPETENCY; PHARMACOGENETICS; PHYSICIAN-PATIENT RELATIONS;

EID: 34748862376     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500425     Document Type: Article

References (22)

1. Nuffield Council on Bioethics. Pharmacogenetics: Ethical Issues. Nuffield Council on Bioethics: London, 2003.
2. Rippe KP, Bachmann A, Faisst K, Oggier W, Pauli-Magnus C, Probst-Hensch N et al. (TA SWISS): Pharmakogenetik und Pharmakogenomik. TA 48/2004. Bern 2004.
3. European Commission. Ethical, Legal and Social Aspects of Genetic Testing: Research, Development and Clinical Applications. Report of the STRATA Expert Group: Brussels, 2004.
4. Mahlknecht U, Voelter-Mahlknecht S. Pharmacogenomics: Questions and concerns. Curr Med Res Opin 2005; 21: 1041-1047.
5. van Delden J, Bolt I, Kalis A, Derijks J, Leufkens H. Tialor-made pharmacotherapy: Future developments and ethical challenges in the field of pharmacogenomics. Bioethics 2004; 18: 303-321.
6. Netzer C, Biller-Andorno N. Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 2004; 18 344-360.
7. Smart A, Martin P, Parker M. Tailored medicine: Whom will it fit? The ethics of patient and disease stratification. Bioethics 2004; 18: 322-343.
8. Schubert L. Ethical implications of pharmacogenetics - do slippery slope arguments matter? Bioethics 2004; 18: 361-378.
9. Lee S. Racializing drug design: Implications of pharmacogenomics for health disparities. Am J Public Health 2005; 95: 2133-2138.
10. Mackenzie R. Reprogenetics and pharmacogenetics: In whose best interests? Med Law 2005; 24: 343-354.
11. La Caze A. Does pharmacogenomics provode and ethical challenge to the utilisation of cost-effectiveness analysis by public health systems? Pharmacoeconomics 2005; 23: 445-447.
12. Marx-Stoelting L. Pharmakogenetik. LIT: Muenster, 2006 accepted.
13. Beauchamp TL, Childress JF. Principles of Biomedical Ethics, 5th edn. Oxford University Press: Oxford, 2001.
14. Schmedders M, Aken Jv, Feuerstein G, Kollek R. Individualized pharmacogenetic therapy: A critical analysis. Community Genet 2003; 6: 114-119.
15. Kollek R, Feuerstein G, Schmedders M, van Aken J. Pharmakogenetik: Implikationen für Patienten und Gesundheitswesen: Anspruch und Wirklichkeit der 'individualisierten Medizin'. Nomos: Baden-Baden, 2004.
16. Gurwitz D, Lunshoff JE, Dedoussis G, Flordellis CS, Fuhr U, Kirchheiner J et al. Pharmacogenomics education: International society of pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenom J 2005; 5: 221-225.
17. Frueh FW, Goodsaid F, Rudman A, Huang SM, Lesko LJ. The need for education in pharmacogenomics: A regulatory perspective. Pharmacogenom J 2005; 5: 218-220.
18. Melzer D, Raven A, Detmer DE, Ling T, Zimmern RL. My Very Own Medicine: What Must I Know? Information Policy for Pharmacogenetics 2003.
19. Morley KI, Hall WD. Using pharmacogenetics and pharmacogenomics in the treatment of pychiatric disorders: Some ethical and economical considerations. J Mol Med 2004; 82: 21-30.
20. Lindpaintner K. Pharmacogenetics and the future of medical practice: conceptual considerations. Pharmacogenomics 2001; 1: 23-26.
21. Green MJ, Botkin JR. 'Genetic Exceptionalism' in medicine: Clarifying the differences between genetic and nongenetic tests. Ann Internal Med 2003; 138: 571-576.
22. Freund CL, Clayton EW. Pharmacogenomics and children: Meeting the ethical challenges. Am J Pharmacogenom 2003; 3: 309-404.